A quick recap of five interesting AIM companies right now with news out today. N4 Pharma Plc (LON:N4P) has completed two studies showing that its Nuvec system, a novel delivery..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant..
N4 Pharma (LON:N4P) has announced a Broker Offer through Turner Pope Investments (TPI) Limited (“TPI”) The Issue Price of the Broker Offer is 2 pence per new ordinary share Existing..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced successful in vitro testing of Nuvec® loaded with two..
N4 Pharma plc (LON:N4P) Chief Executive Officer Nigel Theobald caught up with DirectorsTalk for an exclusive interview to discuss highlights from their operational update, SiRNA, the strong commercial points of..
N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an operational update on its development plans for commercialising..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced a further update on its recent pre-clinical study with..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced an update on its current work programmes. Highlights: · Medicines..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended..
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss encouraging data from its oncology research. Nigel describes the behavior of Nuvec, explains why now a focus on oncology,..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided details of its work plan following the encouraging data..
N4 Pharma Oncology programme initial pilot study – summary of findings N4 Pharma plc (LON:N4P) has successfully completed an in vivo confirmatory oncology study which reinforces the results from an..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a strategic update following data from its proof-of-concept programmes..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that further to the Company’s announcement dated 11 February..
N4 Pharma plc (LON:N4P) Chief Executive Officer Nigel Theobald caught up with DirectorsTalk for an exclusive interview to discuss highlights from their interim results, key findings in the optimisation work,..
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss interim results for the six months ended 30 June 2021. Nigel talks us through the highlights, talks about..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its current in vivo work..
